Market Cap | 15.36M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -20.48M | Forward P/E | -0.79 | EPS next Y | - | 50D Avg Chg | 16.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 42.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -63.00% |
Recommedations | 1.00 | Quick Ratio | 0.20 | Shares Outstanding | 3.14M | 52W Low Chg | 317.00% |
Insider Own | 0.35% | ROA | -73.24% | Shares Float | 2.78M | Beta | 2.56 |
Inst Own | 19.59% | ROE | - | Shares Shorted/Prior | 21.49K/33.78K | Price | 7.09 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,229,174 | Target Price | - |
Oper. Margin | - | Earnings Date | Oct 2 | Volume | 155,729 | Change | 13.26% |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Oppenheimer | Outperform | Jul 11, 23 |
Oppenheimer | Outperform | Apr 6, 23 |